MX9802883A - Method of activating a novel ligand regulatory pathway. - Google Patents

Method of activating a novel ligand regulatory pathway.

Info

Publication number
MX9802883A
MX9802883A MX9802883A MX9802883A MX9802883A MX 9802883 A MX9802883 A MX 9802883A MX 9802883 A MX9802883 A MX 9802883A MX 9802883 A MX9802883 A MX 9802883A MX 9802883 A MX9802883 A MX 9802883A
Authority
MX
Mexico
Prior art keywords
activating
regulatory pathway
methods
novel
pathway
Prior art date
Application number
MX9802883A
Other languages
Spanish (es)
Other versions
MXPA98002883A (en
Inventor
Anthony Pawson
Mark Henkemeyer
Original Assignee
Mount Sinai Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corp filed Critical Mount Sinai Hospital Corp
Publication of MX9802883A publication Critical patent/MX9802883A/en
Publication of MXPA98002883A publication Critical patent/MXPA98002883A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A novel ligand regulatory pathway is disclosed and methods of activating the novel pathway in a cell expressing a ligand for an Eph subfamily receptor tyrosine kinase protein. Methods are provided for identifying substances capable of activating the ligand regulatory pathway. Therapeutic methods for affecting neuronal development and regeneration and pharmaceutical compositions using the substances and Eph subfamily receptor tyrosine kinase proteins are also described.
MXPA/A/1998/002883A 1995-10-13 1998-04-13 Method to activate a regulatory route of noved ligands MXPA98002883A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US551895P 1995-10-13 1995-10-13
US005518 2001-11-08

Publications (2)

Publication Number Publication Date
MX9802883A true MX9802883A (en) 1998-11-29
MXPA98002883A MXPA98002883A (en) 1999-01-15

Family

ID=

Also Published As

Publication number Publication date
JPH11515105A (en) 1999-12-21
WO1997014966A1 (en) 1997-04-24
EP1019728A1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
NO894367D0 (en) SYSTEM AND PROCEDURE FOR QUANTITATIVE DETERMINATION OF THE CONCENTRATIONS OF MORE GASES IN BORESLAM.
HK1016509A1 (en) Method and pharmaceutical composition for regulating lipid concentration
NO893801L (en) PROCEDURE AND APPARATUS FOR INSTALLING NEW ROUTES IN AN EXISTING SUBSTANCES.
DE68928638D1 (en) POLYETHYLENE GLYCOL (PEG) -PROTEIN ADDUCTS AND PROCESS FOR THEIR SEPARATION
NO963792D0 (en) Piperazine derivatives, methods of preparation and preparations containing them
GB9416442D0 (en) Therapeutic heterocycles
DK0663070T3 (en) Method for direct spectrophotometric measurements in unchanged whole blood
AU7386496A (en) An epithelial protein and dna thereof for use in early cancer detection
IL94039A0 (en) Antibodies to anti-cytotoxic proteins
MX9604183A (en) A screening method for identifying ligands for target proteins.
NO902043L (en) PROCEDURE AND APPARATUS FOR ANALYSIS OF SIGENFENOMS IN BORNE FLUIDS.
AU629121B2 (en) Test method and device to assay for total protein
EP0351659A3 (en) Method and arrangement for measuring the concentration of optically active substances
EP0831793A4 (en) Protein particles for therapeutic and diagnostic use
AU4610189A (en) Test method and device for total protein assay
MX9802883A (en) Method of activating a novel ligand regulatory pathway.
DE69016858T2 (en) Method and reagent kit for determining the functional activity of Protein S in human plasma.
EP0876507A4 (en) Manipulation and detection of protein phosphatase 2c - pp2c alpha- expression in tumor cells for cancer therapy, prevention and detection
DE19681207T1 (en) Therapeutic procedures and preparations using rubidium ions
NO305750B1 (en) Substituted benzenesulfonylureas and their use in the preparation of pharmaceutical preparations and pharmaceutical preparations containing the compounds
WO1996040939A3 (en) Expression of functional vertebrate phospholipases in yeast
BR9407357A (en) New tripeptides usable in cns and immune therapy
DK689088D0 (en) HOMOGENOUS AQUE TEST SOLUTION AND PROCEDURES FOR PREPARING THEREOF
DK299590A (en) PHOSPHOLIPID DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND THERAPEUTIC PREPARATIONS CONTAINING THESE
AU6688696A (en) Non-receptor type human protein tyrosine phosphatase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal